189 related articles for article (PubMed ID: 27085744)
21. Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation.
Havasi A; Doros G; Sanchorawala V
Am J Hematol; 2018 May; 93(5):E129-E132. PubMed ID: 29430701
[No Abstract] [Full Text] [Related]
22. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart.
Bar N; Parker TL; Dhodapkar MV
J Clin Oncol; 2015 Nov; 33(32):3689-90. PubMed ID: 26371139
[No Abstract] [Full Text] [Related]
23. Ptosis and macroglossia in a woman with systemic light-chain amyloidosis.
Hsiao PJ; Chang YC; Tsao YH; Wu KL; Kao YH; Chan JS; Wang CH; Lin YY; Chuu CP; Lin YS
Clin Chim Acta; 2019 Jul; 494():112-115. PubMed ID: 30905590
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of AL amyloidosis].
Moreau P
Rev Med Interne; 2001 Jun; 22 Suppl 1():18s-19s. PubMed ID: 11439441
[No Abstract] [Full Text] [Related]
25. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.
Sarosiek S; Zheng L; Sloan JM; Quillen K; Brauneis D; Sanchorawala V
Blood Cancer J; 2020 Sep; 10(8):88. PubMed ID: 32873776
[TBL] [Abstract][Full Text] [Related]
26. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
27. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
28. Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen.
Magagnoli M; Castagna L; Bramanti S; Balzarotti M; Santoro A
Bone Marrow Transplant; 2004 May; 33(10):1067-8. PubMed ID: 15129236
[No Abstract] [Full Text] [Related]
29. Nephrotic syndrome secondary to amyloidosis.
Kneipp S; Himmelstein SB
Nurse Pract; 2000 Jun; 25(6 Pt 1):78, 81, 85-6 passim. PubMed ID: 10884998
[TBL] [Abstract][Full Text] [Related]
30. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
Tan CR; Estrada-Merly N; Landau H; Lekakis L; Banerjee R; Mian H; Usmani SZ; Hanbali A; Lazarus HM; Kyle RA; Dholaria B; Bal S; Strouse C; Murthy HS; Wirk B; Nishihori T; Kumar S; Shah N; Qazilbash M; D'Souza A
Bone Marrow Transplant; 2022 Feb; 57(2):295-298. PubMed ID: 34802047
[No Abstract] [Full Text] [Related]
31. Autologous Hematopoietic Cell Transplantation Versus Chemotherapy Alone for Immunoglobulin Light Chain Amyloidosis: A Retrospective Study.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):413-422.e5. PubMed ID: 31023593
[TBL] [Abstract][Full Text] [Related]
32. Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis.
Furtado VF; Brauneis D; Weinberg J; Elhassan N; Sloan JM; Sanchorawala V
Bone Marrow Transplant; 2022 Feb; 57(2):306-308. PubMed ID: 34845368
[No Abstract] [Full Text] [Related]
33. Localized Lymph Node Light Chain Amyloidosis.
Yamamoto A; Fujii N; Obika M; Yamashita T; Otsuka F
Intern Med; 2020 Oct; 59(19):2415-2418. PubMed ID: 32611959
[TBL] [Abstract][Full Text] [Related]
34. Conventional Therapy for Amyloid Light-Chain Amyloidosis.
Milani P; Palladini G
Acta Haematol; 2020; 143(4):365-372. PubMed ID: 32353854
[TBL] [Abstract][Full Text] [Related]
35. Revisiting complete response in light chain amyloidosis.
Sidana S; Dispenzieri A; Murray DL; Go RS; Buadi FK; Lacy MQ; Gonsalves WI; Dingli D; Warsame R; Kourelis T; Muchtar E; Hayman SR; Kapoor P; Kyle RA; Leung N; Rajkumar SV; Gertz MA; Kumar SK
Leukemia; 2020 May; 34(5):1472-1475. PubMed ID: 31772296
[No Abstract] [Full Text] [Related]
36. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.
Staron A; Zheng L; Doros G; Connors LH; Mendelson LM; Joshi T; Sanchorawala V
Blood Cancer J; 2021 Aug; 11(8):139. PubMed ID: 34349108
[TBL] [Abstract][Full Text] [Related]
37. AA-negative and Kappa-positive Amyloidosis in a Patient with Rheumatoid Arthritis.
Ueno T; Sumida K; Hoshino J; Suwabe T; Mise K; Hazue R; Hayami N; Hiramatsu R; Kawada M; Imafuku A; Hasegawa E; Sawa N; Takaichi K; Kinowaki K; Ohashi K; Fujii T; Nishida A; Ubara Y
Intern Med; 2016; 55(17):2491-5. PubMed ID: 27580556
[TBL] [Abstract][Full Text] [Related]
38. Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience.
Azorín SE; Cibeira MT; Solé M; Fernández de Larrea C; Rosiñol L; Rovira M; Campistol JM; Bladé J
Amyloid; 2017 Mar; 24(sup1):70-71. PubMed ID: 28434321
[No Abstract] [Full Text] [Related]
39. [Multiple myeloma and other plasma cell dyscrasias].
del Potro Gómez E; Morales Sanz D
Rev Clin Esp; 1999 Apr; 199 Suppl 1():52-7. PubMed ID: 10422451
[No Abstract] [Full Text] [Related]
40. ASCT for AL: all's well that ends well.
Wechalekar AD
Blood; 2011 Oct; 118(16):4298-9. PubMed ID: 22021449
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
